Evaxion A (EVAX) Liabilities and Shareholders Equity (2019 - 2026)
Evaxion A (EVAX) posted Liabilities and Shareholders Equity of $23.6 million for Q1 2026, down 16.78% on a QoQ basis from $28.4 million in Q4 2025, and down 6.33% year-over-year from $25.2 million in Q1 2025.
Evaxion A (EVAX) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Evaxion A's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $23.6 million for Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 6.33% year-over-year to $23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.2 million (up 96.84% YoY) and the FY2025 annual result came in at $28.4 million, up 127.54% from the prior year.
- Liabilities and Shareholders Equity was $23.6 million for Q1 2026 at Evaxion A, down from $28.4 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $41.1 million in Q1 2022 and bottomed at $22654.0 in Q1 2024.
- A 5-year average of $21.5 million and a median of $22.2 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity plunged 99.89% — and 2025, when it jumped 111310.79%.
- Evaxion A's Liabilities and Shareholders Equity stood at $22.0 million in 2022, then tumbled by 41.48% to $12.9 million in 2023, then decreased by 3.13% to $12.5 million in 2024, then soared by 127.54% to $28.4 million in 2025, then fell by 16.78% to $23.6 million in 2026.
- Business Quant data shows EVAX's Liabilities and Shareholders Equity at $23.6 million in Q1 2026, $28.4 million in Q4 2025, and $29.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Evaxion A | 25.44 Mn | 25.44 Mn | - | 23.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.64 Mn |
| Dec 31, 2025 | 28.41 Mn |
| Sep 30, 2025 | 29.74 Mn |
| Jun 30, 2025 | 22.45 Mn |
| Mar 31, 2025 | 25.24 Mn |
| Dec 31, 2024 | 12.49 Mn |
| Jun 30, 2024 | 15.23 Mn |
| Mar 31, 2024 | 22,654.00 |
| Dec 31, 2023 | 12.89 Mn |
| Sep 30, 2023 | 11.94 Mn |
| Jun 30, 2023 | 16.75 Mn |
| Mar 31, 2023 | 20.49 Mn |
| Dec 31, 2022 | 22.03 Mn |
| Sep 30, 2022 | 27.45 Mn |
| Jun 30, 2022 | 34.00 Mn |
| Mar 31, 2022 | 41.08 Mn |
| Dec 31, 2021 | 40.16 Mn |
| Sep 30, 2021 | 24.12 Mn |
| Jun 30, 2021 | 27.66 Mn |
| Mar 31, 2021 | 34.92 Mn |